At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study Of Sunitinib Malate In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer
In Brief
A Phase 1 clinical trial evaluating capecitabine, oxaliplatin, and 2 other interventions for Stomach Neoplasms. Completed, enrolled 76 participants across 3 sites.
Detailed Summary
The purpose of the study is to determine the safe and tolerable doses of sunitinib given together with either cisplatin and capecitabine or oxaliplatin and capecitabine in patients who have advanced gastric cancer who have not received prior chemotherapy for their advanced cancer
Study Details
Timeline
Interventions
Capecitabine is given orally at 1000mg/m\^2 twice a day for 14 days followed by 7 days of drug free period.
Oxaliplatin is given 110mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.
Capecitabine is given orally at 1000mg/m\^2 twice a day for 14 days followed by 7 days of drug free period.
Cisplatin is given 80mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.